ANN ARBOR, Mich., June 24 /PRNewswire/ -- NanoBio Corp. announced today that it has been named to the annual FierceBiotech "Fierce 15" list, designating NanoBio as one of the top biotechnology companies of 2008.
The editors of FierceBiotech evaluated hundreds of privately held firms based on company vision, revenue potential, quality of deals, strength of technology, partnerships and competitive market position. NanoBio was determined to be one of the "fiercest," proven by its creativity and innovations in the industry, according to the editors of FierceBiotech.
NanoBio, a spin-out from the University of Michigan, has developed a rich pipeline of anti-infective lotions and vaccines to combat a diverse range of bacteria, viruses and fungi, from MRSA to hepatitis B. Their platform uses a high-energy nanoemulsion to directly target and physically disrupt the outer membranes of pathogens, without toxicity or systemic absorption.
John Carroll, editor of FierceBiotech, said, "This University of Michigan spin-out has advanced its technology on topical agents into phase II trials and promises to make big gains in the way that vaccines are developed and manufactured. The data look promising, a phase III looms, partnerships beckon, and then there's the lure of a possible IPO in the not-too-distant future. For a nano-bio company, NanoBio is well ahead of the pack."
NanoBio's lead treatments are topical lotions for cold sores and nail fungus. Recent data from phase 2 trials demonstrate that their topical treatment for cold sores achieves the efficacy of leading systemic treatments with none of their safety, toxicity or drug interaction concerns. In addition, animal studies indicate that NanoBio's vaccines quickly trigger robust immunity -- without adverse effects -- against a wide array of viruses and bacteria, including influenza, hepatitis B, RSV and anthrax.
"It is really gratifying to have our work recognized by a major voice in the field of biotechnology, especially in an area where so many innovative companies are seeking to improve the health and well being of the global community," said James R. Baker Jr., M.D., founder and chairman of NanoBio Corp. "Being selected as a member of the Fierce 15 is an honor that highlights NanoBio's potential to make a significant impact in the biotech market."
FierceBiotech is an internationally recognized daily newsletter reaching more than 65,000 biotechnology and pharmaceutical industry professionals. The newsletter provides subscribers with a quick, authoritative briefing on the day's top stories, with a special focus on drug discovery and clinical trials.
The Fierce 15 celebrates the spirit of being fierce -- championing innovation and creativity, even in the face of intense competition. The complete list of Fierce 15 companies is available in today's issue of FierceBiotech and on the FierceBiotech Web site at http://www.fiercebiotech.com .
NanoBio(R) Corporation is a privately held biopharmaceutical company focused on developing and commercializing anti-infective products and mucosal vaccines derived from its patented NanoStat(TM) technology platform. The company's lead product candidates are treatments for herpes labialis (cold sores), onychomycosis (nail fungus), MRSA and mucosal vaccines for influenza and hepatitis B. The company's headquarters and laboratory facilities are located in Ann Arbor, Mich.
|SOURCE NanoBio Corporation|
Copyright©2008 PR Newswire.
All rights reserved